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ABSTRACT
Objectives: Randomised controlled trials report
group-level treatment effects. However, an individual
patient confronting a treatment decision needs to know
whether that person’s expected treatment benefit will
exceed the expected treatment harm. We describe a
flexible model for individualising a treatment decision.
It individualises group-level results from randomised
trials using clinical prediction guides.
Methods: We constructed models that estimate the
size of individualised absolute risk reduction (ARR) for
the target outcome that is required to offset
individualised absolute risk increase (ARI) for the
treatment harm. Inputs to the model include estimates
for the individualised predicted absolute treatment
benefit and harm, and the relative value assigned by
the patient to harm/benefit. A decision rule
recommends treatment when the predicted benefit
exceeds the predicted harm, value-adjusted. We also
derived expressions for the maximum treatment harm,
or the maximum relative value for harm/benefit, above
which treatment would not be recommended.
Results: For the simpler model, including one kind of
benefit and one kind of harm, the individualised ARR
required to justify treatment was expressed as required
ARRtarget(i)=ARIharm(i) × RVharm/target(i). A complex model
was also developed, applicable to treatments causing
multiple kinds of benefits and/or harms. We
demonstrated the applicability of the models to
treatments tested in superiority trials (either placebo or
active control, either fixed harm or variable harm) and
non-inferiority trials.
Conclusions: Individualised treatment
recommendations can be derived using a model that
applies clinical prediction guides to the results of
randomised trials in order to identify which individual
patients are likely to derive a clinically important benefit
from the treatment. The resulting individualised
prediction-based recommendations require validation
by comparison with strategies of treat all or treat none.
INTRODUCTION
For questions of treatment and prevention,
randomised controlled trials (RCTs) provide
the most valid evidence concerning the ben-
eﬁts and, often, the harms of the interven-
tion. However, RCTs typically report only
group-level results, whereas treatment effects
may depend importantly on characteristics of
individual patients.
ARTICLE SUMMARY
Article focus
▪ Randomised controlled trials provide relative
group-level estimates of the beneficial and
harmful effects of a treatment. However, the
absolute size of those effects may vary across
individuals according to their baseline risk.
▪ Models have been described previously to indi-
vidualise results of superiority placebo-control
trials in the case of a variable benefit/fixed harm
scenario.
Key messages
▪ We provide a generalised model to individualise
treatment recommendations. We start from the
definition of the Clinically Important Difference:
the size of treatment benefit that offsets the treat-
ment harm, after adjusting for the patient’s
values.
▪ The model applies to a variable benefit and a
fixed or variable harm, and to superiority
(placebo and active control) and non-inferiority
trials. It can accommodate more than one kind
of benefit and/or harm.
▪ Clinical Prediction Guides are used to individual-
ise the predicted risk of the target event and of
the harm at trial entry.
Strengths and limitations of this study
▪ Strengths: the model adopts an individual per-
spective and is flexible and timely. It allows the
calculation of an individual’s maximum predicted
absolute risk increase for the treatment harm, or
the maximum relative value for harm/target, that
would overturn the treatment decision.
▪ Limitations: economic costs are not modelled;
uncertainty will exist for some quantities entering
the model; the model awaits empirical validation.
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A clinical prediction guide (CPG)1–3 uses patient-
speciﬁc risk data to predict the level of risk for a clinical
outcome of interest for an individual patient. CPGs
applied to participants in clinical trials can predict the
individual patient’s level of risk at trial entry (baseline
risk (BLR)) for the target outcome at which the treat-
ment is directed, and also for harm caused by the treat-
ment. If the relative risk reduction for the target
outcome (or relative risk increase for the harm) is con-
stant across the range of BLR, then the absolute treat-
ment effects can be predicted in individual patients:
absolute risk reduction (ARR) for the target outcome
(the treatment beneﬁt) and absolute risk increase (ARI)
for the treatment harm.
But what size of ARR for the target beneﬁt is sufﬁ-
ciently large to justify acceptance of a treatment that
carries with it the potential for beneﬁt and harm? That
depends on the frequency of the harm caused by treat-
ment, and the relative importance of the harm com-
pared to the beneﬁt. The size of treatment beneﬁt that
is large enough to offset the treatment harm is the
patient’s clinically important difference (CID).
The concept of CID has been incorporated in several
prior formulations: the threshold ARR (inverted, the
threshold number needed to treat4), the threshold for
agreeing with treatment,5 the decision threshold
(inverted, the number willing to treat (NWT)).6 Each of
these constructs embodies the concept that for treat-
ment to be justiﬁed, the predicted treatment beneﬁt
must exceed the predicted harm for that individual.
Absolute treatment beneﬁts vary directly with BLR for
the target beneﬁt: for an effective treatment, the higher
the BLR, the greater the predicted absolute beneﬁt.
When modelling absolute treatment effects across indivi-
duals, the assumed model usually has incorporated a
variable beneﬁt, but a ﬁxed harm.4–7 However, the abso-
lute size of treatment harms may also vary across indivi-
duals, in which case a variable beneﬁt/variable harm
model would apply. The two models are illustrated in
ﬁgure 1.
The objectives of this report were: (1) to derive an
expression for CID that is ﬂexible and applicable to
either ﬁxed or variable treatment harm and (2) to
describe a generalised model for deriving a treatment
recommendation based on CID, using group-level esti-
mates of treatment effects provided by RCTs and CPGs
for prediction of individualised absolute treatment
beneﬁt and harm.
METHODS
We deﬁne CID as the size of beneﬁt from the treatment
that offsets the harm of the treatment. We deﬁne a beneﬁt
as the reduction of the occurrence of the target outcome,
expressed as the negative outcome, for example, death,
rather than the positive outcome, for example, survival.
When the beneﬁt is deﬁned categorically, CID is the
required ARR for the target outcome (ARRtarget) obtained
with the treatment compared with the control. The
control can be no treatment (or placebo) or an active
control. The model contains parameters for the predicted
individualised treatment beneﬁt, the predicted individua-
lised treatment harm and the patient’s values. The model
accommodates more than one kind of beneﬁt and more
than one kind of harm. No economic cost, either direct or
indirect, is included in the model.
When applied to individualise a treatment recommen-
dation, the model provides an individualised required
ARRtarget. A decision rule recommends the treatment
when the patient’s predicted ARRtarget is greater than
her required ARRtarget.
Data requirements
Table 1 summarises the required quantities for entry
into the model, distinguishing between group-level mea-
sures and individual-level predictions.
Group-level quantities
Most of the shown group-level quantities are used to
generate individualised estimates. For treatment bene-
ﬁts, the required group-level measure is the relative risk
reduction. The data source can be a meta-analysis of
large RCTs or a single large RCT. The required group-
level quantities for the harms depend on the type of
harm, ﬁxed or variable. For ﬁxed harms, we use a
group-level absolute quantity, the ARI (ARIharm). For
variable harms, we use a group-level relative quantity, the
relative risk increase (RRIharm). Whether ﬁxed or vari-
able, the estimate of the treatment effect for harms
comes from a meta-analysis of large RCTs, a single large
RCT or best available observational evidence. Values are
entered as the relative value (RV) of the harm compared
with the target beneﬁt. A group-level RVharm/target can
be derived from formal utility-based analyses, patient
groups or expert opinion.
Individual-level quantities
The individualised treatment beneﬁt is expressed as
ARR (ARRtarget(i)). The individualised treatment harm is
expressed as ARI (ARIharm(i)). For BLR, we mean the
risk in the reference group (the control arm in the
trial), whether it is represented by patients on no treat-
ment or placebo or by patients on an existing treatment.
Table 2 summarises the role of CPGs in individualising
predicted treatment beneﬁts and harms.
▸ Beneﬁts modelling: The model allows the predicted
ARRtarget(i) to increase for increasing BLRs for the
target outcome (BLRtarget(i)), according to the equa-
tion: predicted ARRtarget(i)=RRRtarget×BLRtarget(i). The
group-level RRRtarget is assumed to be constant across
different BLRs. The BLRtarget(i) for the target beneﬁt
is estimable using a validated CPG.
▸ Harms modelling. In the case of a ﬁxed harm, the
group-level estimate (ARIharm(trial)) is used for the
predicted ARIharm(i). No CPG is needed to predict an
individualised harm. When the receipt of the
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treatment per se is modelled as a ﬁxed harm (as with
risk/discomfort), that harm is experienced by every
treated patient, so the ARIharm(trial) for the harm is
constantly equal to 1.0 (100%). In the case of a vari-
able harm across patients, the predicted ARIharm(i) is
calculated by multiplying the group-level RRIharm by
the individualised BLR for that harm (BLRharm(i)).
The group-level RRIharm is assumed to be constant
across different BLRs. The BLRharm(i) can be esti-
mated using a validated CPG.
▸ Values modelling. An individual RV (RVharm/target(i))
assigned by the patient enters the model. We recog-
nise that an RVharm/target(i) may not be ascertained
reliably. Therefore, we modelled a range of RVs
centred on a group-level RV.
When more than one beneﬁt and/or more than one
harm is included, for each beneﬁt and harm the speciﬁc
ARRi/ARIi/RVi is separately calculated or assigned as
above.
Figure 1 Models for
individualising treatment. Variable
benefit/fixed harm (A) and
variable benefit/variable harm (B)
models are shown. In each
model, treatment benefit,
modelled as absolute risk
reduction for the target event,
varies directly with baseline risk
for the target event. Treatment
harm is modelled as the absolute
risk increase for the harm of
treatment. Harm is then
value-adjusted based on a
relative value (RV) assigned to
the treatment harm as compared
with the target event prevented.
With a fixed harm (A), the
absolute risk increase for the
harm of treatment is constant.
With a variable harm (B), the
absolute risk increase for the
harm of treatment varies with the
baseline risk for the harm. As
indicated by the arrow in each
panel, the point at which the
value-adjusted treatment harm
intersects the treatment benefit
defines the clinically important
difference (CID) for the treatment
benefit.
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Construction of models for individualising a treatment
recommendation
We constructed two models: a simple model where there
is one kind of treatment beneﬁt and one kind of treat-
ment harm; and a complex model where there is more
than one kind of beneﬁt and/or more than one kind of
harm. In both cases, the model equation is solved for
the required ARRtarget(i) to offset the treatment harm(s),
given the predicted ARIharm(i) and RVharm/target(i). The
same basic equation can then be used to calculate:
1. The maximum ARIharm(i) above which treatment
would not be justiﬁed, given the predicted ARRtarget(i)
and RVharm/target(i).
2. The maximum RVharm/target(i) above which treatment
would not be justiﬁed, given the predicted ARRtarget(i)
and ARIharm(i).
RESULTS
Algebraic solution to the model
We derived the following equations to describe the
model (see Appendix for algebraic details).
Simple model: one kind of treatment benefit, one kind of
treatment harm
Required ARRtarget(i)
The required size of the ARRtarget that offsets the treat-
ment harm, value-adjusted, for the patient i can be cal-
culated as (Appendix section 1, equations (1) and (2))
Required ARRtargetðiÞ ¼ ARIharmðiÞ  RVharm=targetðiÞ ðm1Þ
The equation includes the particular condition of a
ﬁxed harm when the ARItrial can substitute for the ARIi.
When the treatment receipt is considered the harm, the
ARItrial is 1.0 and so the ARR(target)i is directly predict-
able from the RVharm/target(i) as
RequiredARRtargetðiÞ ¼ RVharm=targetðiÞ ðm2Þ
Decision rule: In case of ﬁxed harm and variable harm,
the treatment would be justiﬁed for the patient i when
Predicted ARRtargetðiÞ . required ARRtargetðiÞ ðd1Þ
Table 2 Clinical Prediction Guides (CPG) for individualising treatment effects
Type of trial Type of control
CPG to predict control risk for
target event: population
CPG to predict control risk for harm:
population
Superiority trial Placebo or no
treatment
CPG developed on patients on
placebo or no treatment
Fixed harm: CPG not needed
Variable harm: CPG developed on patients
on placebo or no treatment*
Active control
(EET)
CPG developed on patients on EET† Fixed harm: CPG not needed
Variable harm: CPG developed on patients
on EET
Non-inferiority
trial
Active control
(EET)
CPG developed on patients on EET† Fixed harm: CPG not needed
Variable harm: CPG developed on patients
on EET
*If a validated CPG developed on treated patients is used (see worked example on warfarin), the individualised risk for the harm off treatment
can be obtained by dividing the risk on treatment by the group-level relative risk for the harm with the treatment compared with placebo or no
treatment.
†If a validated CPG developed on patients on placebo or no treatment is used, the individualised risk for the target event while on EET can
be obtained by multiplying the risk off treatment by the group-level relative risk for the target event on EET compared with placebo or no
treatment.
EET, established effective therapy.
Table 1 Quantities required for a generalised model for individualising treatment recommendations
Element Group-level measures Individualised predictions
Quantity Measured as Quantity Predicted as
Benefits RRRtrial 1−RRtrial or 1−HRtrial ARRi RRRtrial×BLRi for benefit*
Harms
fixed
variable
ARItrial
RRItrial
Risktreated−control
RRtrial−1 or HRtrial−1
ARIi
ARItrial used as ARIi
RRItrial×BLRi for harm†
Values RV Vharm/Vbenefit RVi Provide a range of RVs centred on typical group-level RV‡
*Estimate BLRi for benefit using CPG for individualised prediction of outcome comprising the benefit.
†Estimate BLRi for a variable harm using CPG for individualised prediction of outcome comprising the harm.
‡Estimate typical RV from formal utility-based analyses, patient groups or expert opinion.
ARItrial, absolute risk increase for a fixed harm; ARRi, ARIi, BLRi, RVi, individualised predicted estimates; BLR, baseline risk (risk in control
group); CPG, clinical prediction guide; HR, hazard ratio; RR, relative risk; RRItrial, relative risk increase for a variable harm, from RCT(s) or
best evidence; RRRtrial, relative risk reduction observed in RCT(s); RV, relative value.
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Maximum ARIharm(i) and maximum RVharm/target(i)
The maximum ARIharm(i) above which the treatment
would not be justiﬁed for the patient i can be calculated as
(Appendix equations (1) and (3))
MaximumARIharmðiÞ ¼ ARRtargetðiÞ=RVharm=targetðiÞ ðm3Þ
Decision rule: The treatment would not be justiﬁed for
the patient i when
PredictedARIharmðiÞ . maximumARIharmðiÞ ðd2Þ
where the predicted ARIharm(i) can be ﬁxed (=ARItrial) or
variable.
Similarly, the maximum RVharm/target(i) above which
the treatment would not be justiﬁed for the patient i can
be calculated as (Appendix equations (1) and (4))
MaximumRVharm=targetðiÞ ¼ ARRtargetðiÞ=ARIharmðiÞ ðm4Þ
Decision rule: The treatment would not be justiﬁed for
the patient i when
Patient's RVharm=targetðiÞ . maximumRVharm=targetðiÞ ðd3Þ
Complex model: multiple treatment benefits, multiple
treatment harms
The model can be generalised to incorporate additional
treatment beneﬁts other than the reduction of the
target outcome, and multiple harms, whether ﬁxed or
variable (Appendix section 2). A harm may have a ﬁxed
as well as a variable component. In that case, the ﬁxed
and variable components would be entered as separate
harms, along with their separate RVs. The size of the
ARRtarget, which is required to offset the value-adjusted
treatment harms and which accounts for other treat-
ment beneﬁts, is calculated for the patient i as
(Appendix equations (5), (6) and (7))
RequiredARRtargetðiÞ ¼
X
ðfor j¼1 to kÞ
ARIharm(j)ðiÞ
 RV(harm(j)=target)ðiÞ

X
ðfor j¼2 tomÞ
ARRbenefit(j)ðiÞ
 RV(benefit(j)=target)ðiÞ ðm5Þ
where k is the number of treatment harms, m is the
total number of treatment beneﬁts, and the beneﬁt(2)
to beneﬁt(m) are the beneﬁts other than the target
beneﬁt. Every RV(i) is expressed as the value assigned to
each outcome, prevented or caused by the treatment,
compared with the value of the target beneﬁt.
Decision rule: Similar to the case of only one beneﬁt
and one harm, the treatment would be justiﬁed for the
patient i when
Predicted ARRtargetðiÞ . required ARRtargetðiÞ ðd1Þ
The complex model can be used to predict the indivi-
dualised maximum allowed ARI for a target harm and
the maximum RV for the target beneﬁt compared with
a target harm, above which the treatment is not justiﬁed.
Applicability of the model
Theoretically, the model is applicable to every situation
tackling the choice between two treatment strategies.
Three examples are proposed to show the applicability
of the model to individualised treatment recommenda-
tions: a superiority trial with a variable beneﬁt/ﬁxed
harm scenario; a superiority trial with a variable
beneﬁt/variable harm scenario and the case of non-
inferiority trials.
Superiority trial: variable benefit, fixed harm. Rosuvastatin
for primary prevention of cardiovascular events
The Justiﬁcation for the Use of Statins in Prevention
( JUPITER) trial8 evaluated the effect of rosuvastatin
versus placebo for reduction of cardiovascular events in
apparently healthy men and women with low-density
lipoprotein cholesterol levels <3.4 mmol/L and elevated
high-sensitivity C reactive protein. The primary outcome
was a composite of myocardial infarction, stroke, arterial
revascularisation, hospitalisation for unstable angina or
cardiovascular death. The group-level result showed a
substantial relative beneﬁt of rosuvastatin (HR 0.56, 95%
CI 0.46 to 0.69). This is equivalent to an RRRtarget of
0.44 (95% CI 0.31 to 0.54). Nevertheless, the individual’s
absolute beneﬁt with rosuvastatin will vary according to
her BLR (BLRi.). Validated CPGs exist to predict the
BLR for cardiovascular events. The Framingham risk
score,9 for example, predicts the risk of cardiovascular
events at 10 years combining risk factors such as age,
gender, smoking, total and high-density lipoprotein chol-
esterol levels, systolic blood pressure and hypertension.
Dorresteijn et al6 used the group-level quantities pro-
vided by the JUPITER study and CPGs, either existing9 10
or newly developed,6 to individualise the predicted BLRi
and absolute effect of rosuvastatin at 10 years
(ARR(target)i) among JUPITER’s participants. They
found an approximate 20-fold variation in the predicted
BLR(target)i. Thus, the predicted ARR(target)i varied from
about 1–20% at 10 years, with a slightly different patient
stratiﬁcation depending on the CPG used. Dorresteijn
and colleagues then evaluated the application of these
individualised predictions to recommend the treatment.
They deﬁned the ‘Number Willing to Treat (NWT)’ as
the number of patients one is willing to treat in
exchange for the prevention of one target outcome
event. Its inverse ratio (1/NWT) was deﬁned as the
‘decision threshold’ and is equivalent to the required
ARR(target)i deﬁned for our model. They considered that
the treatment receipt per se constituted the harm (ﬁxed
harm). Thus, the required ARR(target)i (ie, 1/NWT)
equalled the RVharm/target(i) (m2). They examined how
the treatment recommendations varied across a range of
hypothetical values for NWT.
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Superiority trial: variable benefit, variable harm. Warfarin to
prevent cardioembolic events in patients with atrial
fibrillation
Six RCTs compared warfarin versus placebo/no treat-
ment in patients with non-valvular atrial ﬁbrillation to
reduce the occurrence of stroke and systemic cardioem-
bolism. Hart et al11 meta-analysed those RCTs and found
a pooled RRR for cardioembolic events (RRRstroke) of
0.64—or 64%—(95% CI 0.49 to 0.74). On the other
hand, warfarin was associated with a pooled RRI for
major extracranial bleeding (RRIbleed) of 1.3—or 130%
—(95% CI 0.08 to 3.89; note: Hart et al11 included the
intracranial haemorrhages among the strokes in the efﬁ-
cacy analyses).
Several CPGs to predict the risk of stroke and bleeding
have been developed and validated in patients with atrial
ﬁbrillation. Using the individual predictions for the BLR
for stroke (BLRstroke(i)) and for bleeding (BLRbleed(i)),
the absolute beneﬁcial effect and also the absolute
adverse effect with warfarin can be individualised
as ARRstroke(i)=RRRstroke×BLRstroke(i) and ARIbleed(i)=
RRIbleed×BLRbleed(i), respectively. As an example, for the
prediction of the BLRstroke(i), we adopted the CHADS2
score developed on patients off anticoagulation.12 For
the prediction of the BLRbleed(i), we adopted the
HEMORR2HAGES score.
13 Since the HEMORR2HAGES
score was developed on patients on warfarin,13 the corre-
sponding BLRbleed(i) off warfarin was calculated by divid-
ing the predicted risk on warfarin by 2.3, which is the
reported relative risk for major bleeding for warfarin
compared with placebo.11 The results are shown in
table 3. The predicted ARRstroke(i) varied from 1.22% to
11.65%/year and the predicted ARIbleed(i) varied from
1.07% to 6.95%/year. Comparing the individualised pre-
dictions for the beneﬁt and the harm, value-adjusted, we
then obtained individualised treatment recommenda-
tions for warfarin. A range of plausible values of the
RVbleed/stroke was examined.
Required ARRstroke(i) to justify warfarin
To justify warfarin, the predicted ARRstroke(i) should be
greater than the required ARRstroke(i) (d1), that is,
greater than ARIbleed(i)×RVbleed/stroke(i) (m1). Table 3
summarises the results of the application of the model
to individualise warfarin recommendation in a hypothet-
ical patient population, according to the coclassiﬁcation
of patients based on the CHADS2 and
HEMORR2HAGES scores. We arbitrarily chose a group-
level RV for a bleed/stroke of 0.6, an RV calculated from
a lost-utility analysis over a 10-year time frame.4 Table 3
shows the resulting treatment decisions for each of the
42 cells formed according to the CHADS2 and
HEMORR2HAGES scores.
As a base case, the table was obtained using for
RRRstroke the point estimate (0.64).
11 Since a treatment
is accepted as superior compared with placebo/no treat-
ment only when the upper bound of the 95% CI for the
relative risk for the target outcome is below 1, we
repeated the example using for RRRstroke a value of 0.49
(corresponding to the upper bound for RRstroke 0.51).
In that case, the predicted ARRstroke(i) is reduced and
slightly fewer patients would be recommended for treat-
ment. For example, a CHADS2 3 and HEMORR2HAGES
4 patient would now not be recommended for warfarin
treatment (results not shown). We also repeated the
example, using for RRIbleed a value of 3.89, correspond-
ing to the upper bound of the 95% CI for RRIbleed.
Now, considerably fewer patients would be recom-
mended for treatment (data not shown). The major dif-
ferences in who would be recommended for treatment
arise primarily from the great uncertainty in the estimate
for ARIbleed in this example. We caution that table 3 is
presented only as a framework for presenting particu-
larised treatment recommendations in a variable
beneﬁt/variable harm scenario. The recommendations
shown there are based only on point estimates, and
should not be accepted without taking into account the
uncertainties in the estimates for ARRstroke and ARIbleed
in deriving the treatment recommendations.
Maximum ARIbleed(i) above which warfarin would not be
justified
Figure 2 shows how the maximum ARIbleed(i) (m3) varies
according to the different CHADS2 scores and different
values of RVbleed/stroke(i) centred on a group-level
RVbleed/stroke of 0.6.
Maximum RVbleed/stroke(i) above which warfarin would not be
justified
Similarly, given the CHADS2 and the HEMORR2HAGES
scores of the patient, the model can calculate which is
the maximum RVbleed/stroke(i) (m4) such that if the
patient assigns an RVbleed/stroke higher than this
maximum, warfarin would not be justiﬁed. The variation
of the maximum RVbleed/stroke(i) according to the differ-
ent CHADS2 and HEMORR2HAGES scores is depicted
in ﬁgure 3.
Individualising recommendations for a non-inferior treatment
Application of model to non-inferiority trials
The objective of a non-inferiority trial is to show that the
effect of a new treatment on a target outcome is not
worse, compared with an established effective treatment
(EET), by more than a prespeciﬁed margin. This ‘non-
inferiority margin’ is the maximum loss of efﬁcacy that
is considered acceptable in exchange for a hypothesised
reduction in harm, value-adjusted. At the design phase,
the non-inferiority margin is expressed as either an abso-
lute or relative increase in the target event rate. A group-
level RVharm/beneﬁt is at least implicit when setting the
speciﬁed margin. When interpreting the results of a
non-inferiority trial at the group level, the CI for the
observed treatment effect on the target outcome is com-
pared with the non-inferiority margin. If the bound of
the CI that reﬂects the maximal estimate for inferiority
is less than the margin (does not ‘cover’ the margin),
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Table 3 Framework for application of prognostic risk scores for variable treatment benefit, variable treatment harm to particularise a treatment recommendation
Risk for stroke (CHADS2)
Score 0 1 2 3 4 5 6
Predicted BLRstroke
(%/year) 1.9 2.8 4.0 5.9 8.5 12.5 18.2
Risk for bleed (HEMORR2HAGES)
Predicted ARRstroke
(95% CI) %/year*
1.22 (0.93
to 1.41)
1.79 (1.37
to 2.07)
2.56 (1.96
to 2.96)
3.78 (2.89
to 4.37)
5.44 (4.17
to 6.29)
8.00 (6.13
to 9.25)
11.65 (8.92
to 13.5)
Score
Predicted
BLRbleed,
%/year
warfarin
Predicted ARIbleed
(95% CI)
%/year†
Required ARRstroke
(95% CI)
@ RVbleed/stroke 0.6
%/year Tentative treatment recommendation‡Yes No
0 1.9 0.83 1.07 (0.07 to 3.23) 0.64 (0.04 to 1.94) T T T T T T T
1 2.5 1.09 1.41 (0.09 to 4.24) 0.85 (0.05 to 2.54) T T T T T T T
2 5.3 2.30 3.00 (0.18 to 8.95) 1.80 (0.11 to 5.37) DT CC T T T T T
3 8.4 3.65 4.75 (0.29 to 14.2) 2.85 (0.17 to 8.52) DT DT DT T T T T
4 10.4 4.52 5.88 (0.36 to 17.6) 3.53 (0.22 to 10.6) DT DT DT T T T T
≥ 5 12.3 5.35 6.95 (0.43 to 20.8) 4.17 (0.26 to 12.5) DT DT DT DT T T T
Example: Warfarin versus placebo for stroke reduction in patients with atrial fibrillation.
*Predicted ARRstroke and 95% CI if RRRstroke is 0.64 (0.49 to 0.74) using warfarin.
11
†Predicted ARIbleed and 95% CI if RRIbleed is 1.30 (0.08 to 3.89) using warfarin.
11
‡Tentative treatment recommendations are based on predicted point estimates for ARRstroke and ARIbleed. Uncertainties in these estimates, indicated by 95% CIs above, must also be
considered before actual treatment recommendations can be derived.
ARI, absolute risk increase; ARR, absolute risk reduction; BLR, baseline risk; CC, close all; DT, do not treat; RV, relative value; T, treat.
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then it is concluded that the new treatment is non-
inferior to EET.
In non-inferiority trials, the CID for a patient can be
expressed as the required reduction of the harm which
exactly compensates for the allowed increase of the target
outcome, value-adjusted. Thus, for application to non-
inferiority trials, the equation m1 can be rewritten as:
RequiredARRharmðiÞ ¼ ARItargetðiÞ=RVharm=targetðiÞ
Individualisation of the results of a trial demonstrating
group-level non-inferiority
We individualise group-level results by using CPGs, as
applicable (table 2), to predict BLR(i) and thereby abso-
lute treatment effects on the target outcome (ARItarget(i))
and the treatment harm (ARRharm(i)). ARItarget(i) is
derived as BLRtarget(i) × RRItrial. ARRharm(i) is derived as
BLRharm(i) × RRRtrial. We value-adjust the treatment harm
for the RVharm/target(i). We then compare the individualised
predictions of treatment effects on the target outcome
and on the harm to derive individualised treatment
recommendations. A recommendation to treat with the
non-inferior therapy would result when the predicted
reduction in harm, value-adjusted, exceeds the predicted
loss of efﬁcacy, that is, when ARRharm(i) × RVharm/target(i)
> ARItarget(i) (or, holding the same terminology as for
superiority trials, when predicted ARRharm(i) > required
ARRharm(i)).
Figure 3 Maximum RVbleed/stroke for treatment to be justified,
by CHADS2 score and HEMORR2HAGES score. The scatter
plot shows the variation of the maximum RVbleed/stroke
according to CHADS2 and HEMORR2HAGES (abbreviated as
HEMO) scores. The horizontal lines depict three illustrative
maximum relative values. The model predicts the maximum
RVbleed/stroke to vary over a range between 0.1 (ie, a value
assigned to a stroke 10 times higher than that assigned to a
major bleeding) and about 10 (ie, a value assigned to a major
bleeding 10 times higher than that assigned to a stroke). As
examples, the insert zooms in the results for patients with a
CHADS2 score of 0–2 and HEMO scores of 0, 2 and
4. Among patients with a CHADS2 score of 0, warfarin would
be recommended for HEMO 0 patients if their RVbleed/stroke
were <1.1; for HEMO 2 patients, if their RVbleed/stroke were
<0.4; for HEMO 4 patients if their RVbleed/stroke were <0.2. For
patients with a CHADS2 score of 2, warfarin would be
recommended for HEMO 0 patients if their RVbleed/stroke were
<2.3; for HEMO 2 patients if their RVbleed/stroke were <0.8; for
HEMO 4 patients if their RVbleed/stroke were <0.4. RV, relative
value.
Figure 2 Maximum ARIbleed for treatment to be justified, by
CHADS2 score and relative valuestroke/bleed. The scatter plot
shows the maximum ARIbleed (%/year) above which warfarin
would not be justified, according to the CHADS2 score and
different RVbleed/stroke. The horizontal lines depict the predicted
ARIbleed with warfarin for each HEMORR2HAGES score. As
examples: at RVbleed/stroke 0.6, we would treat CHADS2 score 0
patients only if their predicted ARIbleed given warfarin were less
than 2%/year. Accordingly, we would treat HEMORR2HAGES
score 0–1 patients because their predicted ARIbleed (1.1, 1.4%/
year (table 3)) is less than 2%/year. We would not treat
HEMORR2HAGES score ≥2 patients because their predicted
ARIbleed (3–7%/year (table 3)) is greater than 2%/year. Again at
RVbleed/stroke 0.6, we would treat CHADS2 score 2 patients only
if their predicted ARIbleed were less than 4.3%/year. Thus, we
would treat HEMORR2HAGES score 0–2 patients because
their predicted ARIbleed (1.1–3%/year (table 3)) is less than
4.3%/year. We would not treat HEMORR2HAGES ≥3 patients
because their predicted ARIbleed (4.8–7%/year (table 3)) is
greater than 4.3%/year. At the RVbleed/stroke set higher or lower
than 0.6, fewer patients or more patients, respectively, would
be recommended for treatment according to the model. ARI,
absolute risk increase; RV, relative value.
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To examine the worst case, we then repeat the com-
parison of reduction in harm and loss of efﬁcacy by cal-
culating ARItarget(i) using not the point estimate for
RRItrial but the bound of its CI that reﬂects the maximal
inferiority of the new treatment.
DISCUSSION
We presented an extension of the previously described
models to individualise treatment recommendations,
based on the use of CPGs to predict individual-level
treatment effects, adjusted for the relative importance
assigned by the patient to different outcomes.
Strengths
The adoption of an individual-level perspective repre-
sents the fundamental feature of the model. The indivi-
dualising process requires the conversion of group-level
into individual-level treatment effects and the use of the
patient’s values.14 The model presented here is more
ﬂexible than models for individualising treatment
recommendations described previously.4 5 Either a ﬁxed
or a variable harm is accommodated in our model.
LaHaye et al15 developed a decision aid speciﬁcally
designed to individualise antithrombotic therapy in
patients with atrial ﬁbrillation that included a variable
beneﬁt/variable harm scenario and also the patient’s
RVbleed/stroke. However, they did not explicitly conceptu-
alise and generalise the underlying model. We showed
the adaptability of our model to treatments causing mul-
tiple kinds of beneﬁts and harms, as well as to non-
inferiority trials. The concepts of the maximum ARIharm
and maximum RVharm/beneﬁt that would overturn the
clinical decision had not been developed previously.
The model is timely, given the increasing number of
very large RCTs providing precise group-level estimates
of treatment harms as well as treatment beneﬁts, and
the recent rapid rise in validated CPGs, catalogued and
searchable in EvidenceUpdates,3 which makes the indi-
vidualisation of those group-level quantities more
feasible.
Limitations
In our model, we did not include economic costs, either
direct or indirect. Like clinical beneﬁts and harms, eco-
nomic costs can be ﬁxed or variable across patients. This
raises the question of whether a group-level cost-
effectiveness analysis of a treatment can be individua-
lised.16 A step in that direction is to apply prognostic
models to particularise group-level information on cost-
effectiveness according to the predicted risk and patient
subgroup.17 Our model provides a method for individua-
lising the consequences of treatment. However, analyses
of incremental cost-effectiveness or cost-utility at the
individual level are constrained at present by the lack of
reliable individualised data on the incremental direct
and indirect costs of treatment.
Use and appropriateness of CPGs for individualising
recommendations
We generically explained why, how and when model
building requires the use of CPGs. CPGs are developed
for different purposes. A particular application of a CPG
is to individualise risk predictions in the control group
of an RCT. There are some desirable features of a CPG
for this speciﬁc application. In box 1, we provide an aid
to guide the user in the search for and the evaluation of
an appropriate CPG for individualising the group-level
results of the RCT of interest.
In the case of a variable beneﬁt/variable harm, we
look for two different CPGs to classify the patients
according to the ‘baseline’ risks for the target event
and for the harm. In this case, the predictions result-
ing from this coclassiﬁcation might be constrained by
a possible within-patient correlation between the two
variable risks, since the target event and the harm may
share some risk factors or may not be independent
outcomes.
Box 1 How to use a Clinical Prediction Guide (CPG) on
risk prediction to individualise the results of an RCT
Relevance
Will the CPG help me in making individualised risk predictions for
patients in the control group of the randomized controlled trial
(RCT) of interest?
▸ Were the patients on whom the CPG was developed or vali-
dated similar to the RCT’s control group in regard to their clin-
ical characteristics?
▸ Does the treatment status of the patients on whom the CPG
was developed match that of the RCT’s control group, that is,
each on no treatment or placebo; each on established effective
therapy?
▸ Does the CPG provide the absolute risk (or is it at least deriv-
able) for the outcome of interest (target event or harm), in a
specified period of time, according to risk factors/risk score?
Validity
Are the predictions made by the CPG valid?
▸ How was the CPG developed?
Was the CPG developed on a well defined and representative
sample of patients prospectively followed up?
▸ How well did the CPG perform in the population of derivation?
Was the CPG’s calibration tested? How accurate were the pre-
dictions of the absolute risk, that is, how good was the agree-
ment between predictions and observed outcome?
Were the CPG’s discrimination (c-statistic) and reclassification
tested? How good were they?
Did the CPG undergo internal validation to quantify and even-
tually adjust for overfitting/optimism?
▸ Did the CPG undergo external validation?
– Was the CPG’s performance tested in patients different
from those on whom it was developed? How good was it?
Precision
How precise were the predictions of the absolute risk, that is,
how wide was the uncertainty around the provided estimates?
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Uncertainty in group-level estimates and patient values
The results of an RCT are usually provided as point esti-
mates accompanied by a measure of variability (CI).
Often, as shown in the example in table 3, the within-
trial estimates for the harm have been characterised by
high imprecision. However, this situation may be improv-
ing with the increasing reports of very large active-
control RCTs.18
Probably the major source of uncertainty is the
patient’s RVharm/beneﬁt and its elicitation. The scenario
presented to the patient should uniformly include the
major clinical outcomes of the treatment decision,
including death if relevant, and the time frame of the
consequences of the decision. Decision aids, which are
tools speciﬁcally designed to prepare the patient to par-
ticipate in the decision process, have been shown to
improve patient knowledge and involvement, especially
when they target explicit values clariﬁcation.19
One may embed in the calculation of the individual
quantities a measure of the variance (eg, SE) of the
group-level measures entering the model.20 Additionally,
one may estimate how much that uncertainty can affect
the individual predictions in the most pessimistic direc-
tion, that is, using the CI bounds for the group-level esti-
mate of the treatment effect on target corresponding to
the worst scenario. We proposed an alternative approach
to deal with the uncertainty around the quantities enter-
ing the model. We provided formulas for estimating the
individualised maximum ARIharm and RVharm/beneﬁt
above which the decision to treat would be overturned.
Future research objectives
A. Resolution of uncertainty. In applying our model,
methods are needed to resolve uncertainty arising
from imprecision in the estimates of treatment
beneﬁt and treatment harm derived from group-level
results from RCTs. In this paper, we addressed uncer-
tainty by resorting to sensitivity analyses utilising
bounds of CIs on treatment effects. However, in the
ﬁeld of cost-effectiveness analysis, investigators pro-
gressed to approaches dealing simultaneously with
the stochastic uncertainty of all the quantities enter-
ing the model. These approaches include non-
parametric bootstrapping, Fieller’s theorem and
Bayesian methods.21 We suggest as a future goal that
such methods be explored for their applicability to
resolution of uncertainty in clinical harm/clinical
beneﬁt analyses.
B. Net beneﬁt and model validation. Vickers et al5 con-
ceived a method to empirically test whether indivi-
dualised recommendations based on CPG-based
predictions of absolute treatment effects, value-
adjusted, would actually result in a greater net beneﬁt
in real life compared with a policy of treating all
patients or treating none. The method utilises the
distribution of predicted individualised treatment
effects in the randomly allocated treatment and
control groups of a large RCT. One combines the
patients whose predicted ARRtarget(i) exceeded the
required ARRtarget(i) who were randomised to the
treatment group, and the patients whose predicted
ARRtarget(i) did not exceed their required ARRtarget(i)
who were randomised to the control group. Those
are the respective patients who would or would not
be recommended for treatment and who used
prediction-based treatment in real life. One then
compares the observed outcomes in the trial of that
combined group with the outcomes for the treat-
ment arm of the RCT. The superiority of the
prediction-based policy is validated if its net beneﬁt
is greater than the net beneﬁt of treat all, or treat
none. The empirical result, in the examples of
Vickers et al5 and later Dorresteijn et al,6 was that a
prediction-based policy was superior, but only within
a limited range of the required ARRtarget(i). If the
required ARRtarget(i) was extreme in either the low or
high direction, a policy of treat all or treat none,
respectively, was preferred.
Vickers et al5 and Dorresteijn et al6 used this approach to
validate individualised recommendations in a ﬁxed harm
scenario, where the harm was receipt of the treatment per
se. Nevertheless, the same approach can be used to valid-
ate individualised recommendations in variable harm
scenarios, and for treatments tested in non-inferiority as
well as superiority trials. As with Vickers’ method in
general, individual-patient trial data must be available to
identify the patients whose predicted ARRtarget(i) did or
did not exceed their required ARRtarget(i).
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APPENDIX: ALGEBRAIC DERIVATION OF THE MODELS
Legend:
Target = target outcome that the treatment can prevent
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Harm = any increase of an adverse outcome due to the treatment
CID = clinically important difference
ARR = absolute risk reduction
ARI = absolute risk increase
V = value
RV = relative value
1. Derivation of the simple model (one benefit, one harm)
The CID corresponds to the ARR for the target benefit sufficiently
large to exactly offset the treatment harm. Allowing for a different
value assigned to the target outcome prevented by the treatment
and to the harm caused by the treatment (Vtarget and Vharm,
respectively), the condition at the CID can be expressed algebraic-
ally as:
ARRtarget  Vtarget ¼ ARIharm  Vharm ð1Þ
1.1. Algebraic solution for the required ARRbenefit to offset
the treatment harm
Dividing each side of the equation (1) by Vtarget
ARRtarget ¼ ARIharm  Vharm=Vtarget !
required ARRtarget ¼ ARIharm  RVharm=target ð2Þ
1.2. Algebraic solution for the maximum ARIharm above
which treatment would not be justified
Dividing each side of the equation (1) by Vharm
ARRtarget  Vtarget=Vharm ¼ ARIharm !
ARRtarget  RVtarget=harm ¼ ARIharm !
maximum ARIharm ¼ ARRtarget  RVtarget=harm ð3Þ
or, expressed in terms of RVharm/target
maximum ARIharm ¼ ARRtarget=RVharm=target
1.3. Algebraic solution for the maximum RVharm/target above
which treatment would not be justified
ARRtarget ¼ ARIharm  Vharm=Vtarget !
ARRtarget ¼ ARIharm  RVharm=target
dividing each side of equation by ARIharm
ARRtarget=ARIharm¼ RVharm=target !
maximum RVharm=target ¼ ARRtarget=ARIharm ð4Þ
2. Derivation of the complex model (multiple benefits,
multiple harms)
Legend:
Benefit = any reduction of an adverse outcome additional to the target
outcome.
At the CID, the sum of treatment benefits offsets the sum of treat-
ment harms. Allowing for different values for every outcome prevented
or caused by treatment, this can be expressed algebraically as:
ARRtarget  VtargetþARRbenefitð2Þ  Vbenefitð2Þþ  þARRbenefitðmÞ
VbenefitðmÞ¼ ARIharmð1Þ  Vharmð1Þþ
   þ ARIharmðkÞ  VharmðkÞ
ð5Þ
where m is the total number of treatment benefits, the benefit(2) to
benefit(m) are the benefits other than the target one, and k is the
number of treatment harms. Or, likewise:
ARRtarget  Vtargetþ
P
ðfor j ¼ 2 to mÞ ARRbenefitðjÞ  Vbenefitð jÞ¼
P
ðfor j¼1 to kÞ
ARIharmð jÞ  Vharmð jÞ
ð6Þ
Subtracting
P
ðfor j ¼ 2 to mÞ ARRbenefitð jÞ  Vbenefitð jÞ from both sides and
dividing both sides for Vtarget, we can obtain the required ARRtarget
such that the total treatment benefits offset the total treatment harms:
required ARRtarget ¼
X
ðfor j ¼ 1 to kÞ ARIharmð jÞ  RVharmð jÞ=target

X
ð for j ¼ 2 to mÞ ARRbenefitðjÞ  RVbenefitð jÞ=target
ð7Þ
where every RV is expressed as the value of that outcome, prevented
or caused by the treatment, compared with the value assigned to the
target outcome.
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